Obesity risk is associated with altered cerebral glucose metabolism and decreased μ-opioid and CB1 receptor availability

dc.contributor.authorKantonen Tatu
dc.contributor.authorPekkarinen Laura
dc.contributor.authorKarjalainen Tomi
dc.contributor.authorBucci Marco
dc.contributor.authorKalliokoski Kari
dc.contributor.authorHaaparanta-Solin Merja
dc.contributor.authorAarnio Richard
dc.contributor.authorDickens Alex M.
dc.contributor.authorvon Eyken Annie
dc.contributor.authorLaitinen Kirsi
dc.contributor.authorHouttu Noora
dc.contributor.authorKirjavainen Anna K.
dc.contributor.authorHelin Semi
dc.contributor.authorHirvonen Jussi
dc.contributor.authorRönnemaa Tapani
dc.contributor.authorNuutila Pirjo
dc.contributor.authorNummenmaa Lauri
dc.contributor.organizationfi=PET-keskus|en=Turku PET Centre|
dc.contributor.organizationfi=Turun biotiedekeskus|en=Turku Bioscience Centre|
dc.contributor.organizationfi=biolääketieteen laitos|en=Institute of Biomedicine|
dc.contributor.organizationfi=bioteknologian laitos|en=Department of Life Technologies|
dc.contributor.organizationfi=psykologia|en=Psychology|
dc.contributor.organizationfi=sisätautioppi|en=Internal Medicine|
dc.contributor.organizationfi=tyks, vsshp|en=tyks, varha|
dc.contributor.organization-code1.2.246.10.2458963.20.14646305228
dc.contributor.organization-code1.2.246.10.2458963.20.15586825505
dc.contributor.organization-code1.2.246.10.2458963.20.40502528769
dc.contributor.organization-code1.2.246.10.2458963.20.66532595361
dc.contributor.organization-code1.2.246.10.2458963.20.77952289591
dc.contributor.organization-code2609201
dc.contributor.organization-code2609810
dc.contributor.organization-code2609820
dc.converis.publication-id67757504
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/67757504
dc.date.accessioned2025-08-28T02:47:26Z
dc.date.available2025-08-28T02:47:26Z
dc.description.abstract<h3>Background</h3><p>Obesity is a pressing public health concern worldwide. Novel pharmacological means are urgently needed to combat the increase of obesity and accompanying type 2 diabetes (T2D). Although fully established obesity is associated with neuromolecular alterations and insulin resistance in the brain, potential obesity-promoting mechanisms in the central nervous system have remained elusive. In this triple-tracer positron emission tomography study, we investigated whether brain insulin signaling, μ-opioid receptors (MORs) and cannabinoid CB<sub>1</sub> receptors (CB<sub>1</sub>Rs) are associated with risk for developing obesity.</p><h3>Methods</h3><p>Subjects were 41 young non-obese males with variable obesity risk profiles. Obesity risk was assessed by subjects’ physical exercise habits, body mass index and familial risk factors, including parental obesity and T2D. Brain glucose uptake was quantified with [<sup>18</sup>F]FDG during hyperinsulinemic euglycemic clamp, MORs were quantified with [<sup>11</sup>C]carfentanil and CB<sub>1</sub>Rs with [<sup>18</sup>F]FMPEP-<em>d</em><sub><em>2</em></sub>.</p><h3>Results</h3><p>Subjects with higher obesity risk had globally increased insulin-stimulated brain glucose uptake (19 high-risk subjects versus 19 low-risk subjects), and familial obesity risk factors were associated with increased brain glucose uptake (38 subjects) but decreased availability of MORs (41 subjects) and CB<sub>1</sub>Rs (36 subjects).</p><h3>Conclusions</h3><p>These results suggest that the hereditary mechanisms promoting obesity may be partly mediated via insulin, opioid and endocannabinoid messaging systems in the brain.</p>
dc.format.pagerange400
dc.format.pagerange407
dc.identifier.eissn1476-5497
dc.identifier.jour-issn0307-0565
dc.identifier.olddbid209707
dc.identifier.oldhandle10024/192734
dc.identifier.urihttps://www.utupub.fi/handle/11111/49292
dc.identifier.urnURN:NBN:fi-fe2021120158516
dc.language.isoen
dc.okm.affiliatedauthorKantonen, Tatu
dc.okm.affiliatedauthorPekkarinen, Laura
dc.okm.affiliatedauthorKarjalainen, Tomi
dc.okm.affiliatedauthorBucci, Marco
dc.okm.affiliatedauthorKalliokoski, Kari
dc.okm.affiliatedauthorHaaparanta-Solin, Merja
dc.okm.affiliatedauthorAarnio, Richard
dc.okm.affiliatedauthorDickens, Alex
dc.okm.affiliatedauthorVon Eyken Bonafonte, Annie
dc.okm.affiliatedauthorLaitinen, Kirsi
dc.okm.affiliatedauthorHouttu, Noora
dc.okm.affiliatedauthorKirjavainen, Anna
dc.okm.affiliatedauthorHelin, Semi
dc.okm.affiliatedauthorHirvonen, Jussi
dc.okm.affiliatedauthorRönnemaa, Tapani
dc.okm.affiliatedauthorNuutila, Pirjo
dc.okm.affiliatedauthorNummenmaa, Lauri
dc.okm.affiliatedauthorDataimport, tyks, vsshp
dc.okm.discipline3121 Internal medicineen_GB
dc.okm.discipline3121 Sisätauditfi_FI
dc.okm.internationalcopublicationnot an international co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA1 ScientificArticle
dc.publisherSpringer Nature
dc.publisher.countryUnited Kingdomen_GB
dc.publisher.countryBritanniafi_FI
dc.publisher.country-codeGB
dc.relation.doi10.1038/s41366-021-00996-y
dc.relation.ispartofjournalInternational Journal of Obesity
dc.relation.volume46
dc.source.identifierhttps://www.utupub.fi/handle/10024/192734
dc.titleObesity risk is associated with altered cerebral glucose metabolism and decreased μ-opioid and CB1 receptor availability
dc.year.issued2022

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
s41366-021-00996-y.pdf
Size:
1.29 MB
Format:
Adobe Portable Document Format
Description:
Publisher's PDF